Skip to main content

Recursion Pharmaceuticals, Inc.

RXRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001601830

In the last 90 days, Recursion Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 4 sales; 344 institutions reported holding it in 13F filings for Q2 2026, worth $1.33B in total; ARK Invest is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Recursion Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
4 filings
2 insiders, $435.0K in total
Insiders trading
2
Net value
−$435.0K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Recursion Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Recursion Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Taylor Ben RChief Financial Officer1,071,462Sep 16, 202612
Khan NajatCEO and President2,072,890Sep 10, 202610
Borgeson BlakeDirector6,158,287Sep 2, 202611
Hallett DavidChief Scientific Officer1,043,837Aug 18, 20264
Dar ZavainDirector240,764Jul 2, 20265
Li Dean YDirector1,473,329Jul 2, 20265
Hershberg RobertDirector162,156Jun 22, 20261
Sun Elaine DDirector135,981Jun 22, 20261
Michor FranziskaDirector215,477Jun 22, 20261
Bumpus NamandjeDirector127,632Jun 22, 20262
Gibson ChristopherDirector883,735Jun 5, 202618
Mauro David JChief Medical Officer225,429Nov 19, 20240
Secora MichaelChief Financial Officer1,487,694Nov 19, 20240
Larson Tina MarriottPresident and COO506,852Nov 19, 20240
Burrell Terry-AnnDirector71,254Jul 3, 20240
Chavez R. MartinDirector60,078Apr 3, 20240
Virani ShafiqueChief Business Officer136,748Jan 18, 20240
Bogue ZacharyDirector, 10% Owner9,378Jul 6, 20230
Mamoura Diversified Global Holding PJSC10% Owner12,985,927IndirectMar 3, 20230
Mubadala Investment Co PJSC10% Owner12,985,927IndirectMar 3, 20230
Doyle RamonaChief Medical Officer121,110May 18, 20220
Lux Ventures IV, L.P.Other: Former 10% Owner13,021,519Dec 9, 20210
Lux Venture Partners IV, LLCOther: Former 10% Owner13,021,519Dec 9, 20210
Hebert PeterOther: Former 10% Owner13,021,519Dec 9, 20210
Lux Co-Invest Partners, LLCOther: Former 10% Owner13,021,519Dec 9, 20210
Lux Co-Invest Opportunities, L.P.Other: Former 10% Owner13,021,519Dec 9, 20210
Wolfe JoshOther: Former 10% Owner13,021,519Dec 9, 20210
Mic Capital Partners (Public) (US) Im, LLCOther: See remarks–Nov 3, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 10, 2026 (view filing)5:55 PM ETSep 82 daysKhan NajatCEO and PresidentSSaleClass A Common Stock−22.4K$3.52−$78.8K−1.1%2.07M after10b5-1
Sep 2, 2026 (view filing)6:01 PM ETSep 11 dayBorgeson BlakeDirectorSSaleClass A Common Stock−30.0K$3.34−$100.2K−0.5%6.16M after10b5-1
Aug 6, 2026 (view filing)5:09 PM ETAug 42 daysBorgeson BlakeDirectorSSaleClass A Common Stock−30.0K$3.25−$97.5K−0.5%6.19M after10b5-1
Jul 9, 2026 (view filing)6:04 PM ETJul 72 daysBorgeson BlakeDirectorSSaleClass A Common Stock−40.0K$3.96−$158.5K−0.6%6.22M after10b5-1
Jun 22, 2026 (view filing)Jun 184 daysBumpus NamandjeDirectorSSaleClass A Common Stock−3.96K$3.18−$12.6K−3.0%127.6K after10b5-1
Jun 5, 2026 (view filing)Jun 5Same dayKhan NajatCEO and PresidentSSaleClass A Common Stock−23.6K$3.58−$84.4K−1.1%2.18M after10b5-1
Jun 5, 2026 (view filing)Jun 5Same dayGibson ChristopherDirectorSSaleClass A Common Stock−40.0K$3.62−$144.8K−4.3%883.7K after10b5-1
Jun 4, 2026 (view filing)Jun 31 dayBumpus NamandjeDirectorSSaleClass A Common Stock−4.39K$3.54−$15.5K−9.2%43.2K after10b5-1
Jun 4, 2026 (view filing)Jun 22 daysBorgeson BlakeDirectorSSaleClass A Common Stock−30.0K$3.68−$110.4K−0.5%6.17M after10b5-1
May 27, 2026 (view filing)May 225 daysGibson ChristopherDirectorSSaleClass A Common Stock−40.0K$3.08−$123.2K−4.3%883.7K after10b5-1
May 8, 2026 (view filing)May 71 dayGibson ChristopherDirectorSSaleClass A Common Stock−40.0K$3.37−$134.8K−4.1%926.6K after10b5-1
May 7, 2026 (view filing)May 52 daysBorgeson BlakeDirectorSSaleClass A Common Stock−30.0K$3.52−$105.6K−0.5%6.20M after10b5-1
Apr 24, 2026 (view filing)Apr 222 daysGibson ChristopherDirectorSSaleClass A Common Stock−40.0K$3.61−$144.4K−4.2%906.6K after10b5-1
Apr 8, 2026 (view filing)Apr 71 dayGibson ChristopherDirectorSSaleClass A Common Stock−40.0K$3.10−$124.0K−4.2%906.6K after10b5-1
Apr 8, 2026 (view filing)Apr 71 dayBorgeson BlakeDirectorSSaleClass A Common Stock−30.0K$3.10−$93.0K−0.5%6.23M after10b5-1
Mar 25, 2026 (view filing)Mar 232 daysGibson ChristopherDirectorSSaleClass A Common Stock−40.0K$3.25−$130.0K−4.2%906.6K after10b5-1
Mar 18, 2026 (view filing)Mar 171 dayTaylor Ben RChief Financial OfficerSSaleClass A Common Stock−7.96K$3.39−$27.0K−0.7%1.18M after10b5-1
Mar 11, 2026 (view filing)Mar 92 daysKhan NajatCEO and PresidentSSaleClass A Common Stock−28.3K$3.35−$94.8K−1.2%2.26M after10b5-1
Mar 4, 2026 (view filing)Mar 31 dayBorgeson BlakeDirectorSSaleClass A Common Stock−170.0K$3.46−$588.2K−2.6%6.26M after10b5-1
Feb 19, 2026 (view filing)Feb 19Same dayGibson ChristopherDirectorSSaleClass A Common Stock−40.0K$3.46−$138.4K−4.2%906.6K after10b5-1
Feb 19, 2026 (view filing)Feb 181 dayTaylor Ben RChief Financial OfficerSSaleClass A Common Stock−13.4K$3.08−$41.4K−1.1%1.20M after10b5-1
Feb 6, 2026 (view filing)Feb 42 daysGibson ChristopherDirectorSSaleClass A Common Stock−40.0K$4.12−$164.8K−4.2%913.8K after10b5-1
Feb 6, 2026 (view filing)Feb 33 daysLateBorgeson BlakeDirectorSSaleClass A Common Stock−220.0K$4.20−$924.0K−3.3%6.43M after10b5-1
Jan 22, 2026 (view filing)Jan 202 daysGibson ChristopherDirectorSSaleClass A Common Stock−40.0K$4.47−$178.8K−4.2%913.8K after10b5-1
Jan 8, 2026 (view filing)Jan 62 daysBorgeson BlakeDirectorSSaleClass A Common Stock−220.0K$4.36−$959.2K−3.2%6.65M after10b5-1
Jan 7, 2026 (view filing)Jan 52 daysGibson ChristopherDirectorSSaleClass A Common Stock−40.0K$4.25−$170.0K−4.1%933.8K after10b5-1
Dec 30, 2025 (view filing)Dec 291 dayTaylor Ben RChief Financial OfficerSSaleClass A Common Stock−21.4K$4.18−$89.4K−2.7%761.5K after10b5-1
Dec 29, 2025 (view filing)Dec 227 daysKhan NajatChief R&D Commercial OfficerSSaleClass A Common Stock−124.4K$4.41−$548.6K−16.9%611.1K after10b5-1
Dec 19, 2025 (view filing)Dec 19Same dayGibson ChristopherChief Executive OfficerSSaleClass A Common Stock−40.0K$4.50−$180.0K−4.2%913.8K after10b5-1
Dec 5, 2025 (view filing)Dec 41 dayGibson ChristopherChief Executive OfficerSSaleClass A Common Stock−40.0K$4.63−$185.2K−4.1%933.8K after10b5-1
Dec 4, 2025 (view filing)Dec 22 daysBorgeson BlakeDirectorSSaleClass A Common Stock−220.0K$4.37−$961.4K−3.1%6.87M after10b5-1
Nov 19, 2025 (view filing)Nov 19Same dayGibson ChristopherChief Executive OfficerSSaleClass A Common Stock−40.0K$4.16−$166.4K−4.2%913.8K after10b5-1
Nov 6, 2025 (view filing)Nov 42 daysGibson ChristopherChief Executive OfficerSSaleClass A Common Stock−40.0K$5.21−$208.4K−3.9%974.2K after10b5-1
Oct 24, 2025 (view filing)Oct 231 dayGibson ChristopherChief Executive OfficerSSaleClass A Common Stock−100.0K$5.70−$570.0K−9.5%954.2K after10b5-1
Oct 10, 2025 (view filing)Oct 10Same dayGibson ChristopherChief Executive OfficerSSaleClass A Common Stock−100.0K$6.04−$604.0K−9.3%974.2K after10b5-1
Sep 26, 2025 (view filing)Sep 251 dayGibson ChristopherChief Executive OfficerSSaleClass A Common Stock−100.0K$4.76−$476.0K−9.5%954.2K after10b5-1
Sep 12, 2025 (view filing)Sep 102 daysGibson ChristopherChief Executive OfficerSSaleClass A Common Stock−100.0K$4.71−$471.0K−9.3%974.2K after10b5-1
Aug 28, 2025 (view filing)Aug 262 daysGibson ChristopherChief Executive OfficerSSaleClass A Common Stock−100.0K$4.84−$484.0K−9.5%954.2K after10b5-1
Aug 19, 2025 (view filing)Aug 181 dayKhan NajatChief R&D Commercial OfficerSSaleClass A Common Stock−36.6K$5.52−$202.0K−5.2%668.2K after
Aug 13, 2025 (view filing)Aug 112 daysGibson ChristopherChief Executive OfficerSSaleClass A Common Stock−500.3K$5.28−$2.64M−33.2%1.00M after10b5-1
Aug 13, 2025 (view filing)Aug 112 daysGibson ChristopherChief Executive OfficerSSaleClass A Common Stock−117.9K$5.28−$622.4K−100.0%0 after2 lots10b5-1
Mar 28, 2025 (view filing)Mar 271 dayGibson ChristopherChief Executive OfficerSSaleClass A Common Stock−138.6K$6.04−$837.0K−11.0%1.12M after10b5-1
Mar 7, 2025 (view filing)Mar 5-62 daysGibson ChristopherChief Executive OfficerSSaleClass A Common Stock−40.0K$6.48−$259.0K−3.1%1.26M after2 lots10b5-1
Feb 7, 2025 (view filing)Feb 5-62 daysGibson ChristopherChief Executive OfficerSSaleClass A Common Stock−40.0K$7.90−$316.0K−3.0%1.27M after2 lots10b5-1
Jan 13, 2025 (view filing)Jan 8-105 daysGibson ChristopherChief Executive OfficerSSaleClass A Common Stock−40.0K$7.18−$287.2K−5.2%736.6K after2 lots10b5-1
Dec 6, 2024 (view filing)Dec 4-52 daysGibson ChristopherChief Executive OfficerSSaleClass A Common Stock−40.0K$7.14−$285.6K−5.2%736.6K after2 lots10b5-1
Nov 15, 2024 (view filing)Nov 13-142 daysGibson ChristopherChief Executive OfficerSSaleClass A Common Stock−40.0K$7.55−$301.8K−5.0%762.7K after2 lots10b5-1
Nov 14, 2024 (view filing)Nov 122 daysBorgeson BlakeDirectorSSaleClass A Common Stock−11.4K$7.64−$87.5K−0.2%7.07M after10b5-1
Nov 14, 2024 (view filing)Nov 12-132 daysSecora MichaelChief Financial OfficerSSaleClass A Common Stock−30.0K$7.65−$229.5K−2.0%1.50M after2 lots10b5-1
Oct 31, 2024 (view filing)Oct 292 daysBorgeson BlakeDirectorSSaleClass A Common Stock−11.4K$6.72−$76.9K−0.2%7.08M after10b5-1